Dr Andrew Harvey

Prior to joining UniQuest, Andrew was the Vice President of Drug Discovery at Bionomics Limited (Adelaide, Australia), a publicly-listed discovery and development company working across oncology, neuroscience and inflammation.

In this role, he was responsible for leading chemistry and IP in programs ranging from hit identification to phase II clinical development, including two programs partnered with Merck & Co. While at Bionomics, Andrew worked closely with the Cancer Therapeutics Cooperative Research Centre (CTx) as an industry partner and a member of the CTx operations group.

Previously, Andrew was an NHMRC Industry Fellow at the Walter and Eliza Hall Institute (Melbourne, Australia), where his research focused on autoimmune disease. He obtained his PhD in biological chemistry at the University of Canterbury (Christchurch, New Zealand).